US Patent

US9198892 — Composition and/or method for preventing onset and/or recurrence of cardiovascular events

Method of Use · Assigned to Mochida Pharmaceutical Co Ltd · Expires 2027-09-25 · 1y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a composition and/or method for preventing cardiovascular events in patients who have had cardiovascular angioplasty or are being treated for hyperlipidemia.

USPTO Abstract

Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.

Drugs covered by this patent

Vascepa (ICOSAPENT ETHYL) · Amarin Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2706`	—	Vascepa
`U-2706`	—	Vascepa

Patent Metadata

Patent number: US9198892
Jurisdiction: US
Classification: Method of Use
Expires: 2027-09-25
Drug substance claim: No
Drug product claim: No
Assignee: Mochida Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.